Evaluation of P-glycoprotein influence on carbamazepine pharmacokinetics in epileptics rats

Vol. 1, 2019. - 116683
Pôster
Favorite this paper
How to cite this paper?
Abstract

Epilepsy is a worldwide disease. About 30% of these patients do not respond to treatment due to the influence of efflux transporters, especially P-glycoprotein (Pg-P), of which antiepileptics are substrates. Given the above, the present work aimed to evaluate the pharmacokinetics of carbamazepine, comparing healthy and epileptic rats, and the use of Pg-P inhibitors. (Protocol Ethics Committee CEUA/UNIFAL-MG No. 32/2017). Carbamazepine was administered 25 mg/kg to healthy and epileptic animals, induced by chemical model of pilocarpine-induced epilepsy. The pharmacokinetics of carbamazepine administered together with Pg-P inhibitor verapamil were also evaluated. Blood samples were taken from 0-8 hours. The analysis was done in UHPLC-MS/MS. No statistical differences were observed between the control and epileptic groups, even with the use of Pg-P inhibitor. These results may be explained by the fact that carbamazepine is not an ideal Pg-P substrate in rats.

Institutions
  • 1 Universidade Federal de Alfenas
Track
  • Toxicology
Keywords
Epilepsy
pharmacokinetic
Carbamazepine